玻璃体内注射贝伐单抗作为晚期伊尔斯病玻璃体切除术的辅助治疗手段。
Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales' disease.
作者信息
Thakar Meenakshi, Bamrolia Naina R, Raina Usha Kaul, Ghosh Basudeb
机构信息
Maulana Azad Medical College, New Delhi, India.
出版信息
J Ophthalmic Inflamm Infect. 2012 Jun;2(2):105-8. doi: 10.1007/s12348-011-0049-3. Epub 2011 Nov 17.
PURPOSE
This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales' disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery.
METHOD
In two patients presenting with vitreous haemorrhage, retinal neovascularisation and localised tractional retinal detachment, 1.25 mg of intravitreal bevacizumab was injected prior to vitrectomy, membrane peeling and endolaser photocoagulation of retina.
RESULT
Regression of the retinal neovascularisation with resolution of dye leakage on fluoroscein angiography was observed in both cases. Membrane peeling could be performed with minimal bleeding during vitreoretinal surgery in both cases.
CONCLUSION
Bevacizumab may be a possible adjunctive treatment to vitreoretinal surgery for the management of Eales' disease with tractional retinal detachment.
目的
本研究旨在报告玻璃体内注射贝伐单抗作为辅助治疗手段，用于两例晚期伊尔斯病伴玻璃体积血和牵引性视网膜脱离患者，在玻璃体视网膜手术之前的应用情况。
方法
两名出现玻璃体积血、视网膜新生血管形成和局限性牵引性视网膜脱离的患者，在玻璃体切割术、视网膜前膜剥离术和视网膜激光光凝术之前，接受了1.25毫克玻璃体内贝伐单抗注射。
结果
两例患者均观察到视网膜新生血管消退，荧光素血管造影显示染料渗漏消失。两例患者在玻璃体视网膜手术期间进行视网膜前膜剥离时出血均很少。
结论
对于伴有牵引性视网膜脱离的伊尔斯病，贝伐单抗可能是玻璃体视网膜手术的一种辅助治疗方法。
Zotero 插件